Cargando…

Management of a severe bilateral pulmonary embolism as a complication of VITT following vaccination with AstraZeneca COVID-19 vaccine

Since the start of vaccination against COVID-19 viral infection using adenovirus-based vector vaccine (eg, The Oxford–AstraZeneca vaccine, using the modified chimpanzee adenovirus ChAdOx1, and the Johnson & Johnson vaccine, using human adenovirus serotype 26), a rare, but potentially life-threat...

Descripción completa

Detalles Bibliográficos
Autores principales: Elkoumy, Mohammed, Schoen, Julika, Loew, Andreas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096475/
https://www.ncbi.nlm.nih.gov/pubmed/35545306
http://dx.doi.org/10.1136/bcr-2021-246770
Descripción
Sumario:Since the start of vaccination against COVID-19 viral infection using adenovirus-based vector vaccine (eg, The Oxford–AstraZeneca vaccine, using the modified chimpanzee adenovirus ChAdOx1, and the Johnson & Johnson vaccine, using human adenovirus serotype 26), a rare, but potentially life-threatening complication called vaccine-induced thrombotic thrombocytopenia (VITT) was reported. As the number of cases increases every day, with the increase in the number of vaccinated people all over the world, this complication is a concern to the medical field. We report a case on the acute management of a patient who presented to us with life-threatening bilateral pulmonary embolism as a complication of VITT after the first dose of vaccination with Oxford–AstraZeneca vaccine against COVID-19.